Cargando…

Fluorescent Antibody Studies in Malignant Melanoma

Sera from 57 patients with malignant melanoma and 39 control patients were tested by immunofluorescence techniques against 6 melanoma cell lines. Thirty-two per cent of tests with sera from melanoma patients showed fluorescence with these cell lines whereas only 17% of tests with control sera were p...

Descripción completa

Detalles Bibliográficos
Autor principal: Whitehead, R. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1973
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008930/
https://www.ncbi.nlm.nih.gov/pubmed/4205845
_version_ 1782136013035929600
author Whitehead, R. H.
author_facet Whitehead, R. H.
author_sort Whitehead, R. H.
collection PubMed
description Sera from 57 patients with malignant melanoma and 39 control patients were tested by immunofluorescence techniques against 6 melanoma cell lines. Thirty-two per cent of tests with sera from melanoma patients showed fluorescence with these cell lines whereas only 17% of tests with control sera were positive. Reactions occurred in 21% of tests with sera from patients with primary melanoma compared with 40% with secondary melanomata and 54% with “cured” melanomata. The cell lines varied in antigenicity but this did not correlate with either pigmentation or length of time in culture. The cell lines which were most reactive with sera from melanoma patients were also most reactive with control sera.
format Text
id pubmed-2008930
institution National Center for Biotechnology Information
language English
publishDate 1973
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20089302009-09-10 Fluorescent Antibody Studies in Malignant Melanoma Whitehead, R. H. Br J Cancer Articles Sera from 57 patients with malignant melanoma and 39 control patients were tested by immunofluorescence techniques against 6 melanoma cell lines. Thirty-two per cent of tests with sera from melanoma patients showed fluorescence with these cell lines whereas only 17% of tests with control sera were positive. Reactions occurred in 21% of tests with sera from patients with primary melanoma compared with 40% with secondary melanomata and 54% with “cured” melanomata. The cell lines varied in antigenicity but this did not correlate with either pigmentation or length of time in culture. The cell lines which were most reactive with sera from melanoma patients were also most reactive with control sera. Nature Publishing Group 1973-12 /pmc/articles/PMC2008930/ /pubmed/4205845 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Articles
Whitehead, R. H.
Fluorescent Antibody Studies in Malignant Melanoma
title Fluorescent Antibody Studies in Malignant Melanoma
title_full Fluorescent Antibody Studies in Malignant Melanoma
title_fullStr Fluorescent Antibody Studies in Malignant Melanoma
title_full_unstemmed Fluorescent Antibody Studies in Malignant Melanoma
title_short Fluorescent Antibody Studies in Malignant Melanoma
title_sort fluorescent antibody studies in malignant melanoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008930/
https://www.ncbi.nlm.nih.gov/pubmed/4205845
work_keys_str_mv AT whiteheadrh fluorescentantibodystudiesinmalignantmelanoma